Resected Pancreatic Cancer: Why Wait for the Inevitable?Resected Pancreatic Cancer: Why Wait for the Inevitable?
Dr. John Marshall reports on a retrospective study suggesting that maintenance with capecitabine is a promising option in patients with resected pancreatic adenocarcinoma after adjuvant therapy. Medscape Oncology
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Hematology-Oncology Commentary Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastroenterology | Hematology | Pancreas | Pancreatic Cancer | Study | Xeloda